A Prospective, Single-center, Open, Single-arm, Single-dose Clinical Study Evaluating the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adults with Wilson Disease
Latest Information Update: 20 Feb 2025
At a glance
- Drugs LY M003 (Primary)
- Indications Hepatolenticular degeneration
- Focus Adverse reactions
Most Recent Events
- 25 Oct 2024 New trial record